Latest Personalis News & Updates

See the latest news and media coverage for Personalis. We track all announcements, press releases, and industry mentions in real time, all in one place.

Personalis

Cancer genomics and diagnostics company

personalis.com

Headquarters: Fremont, United States
Founded year: 2011
Company type: Public company
Number of employees: 400–500
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about Personalis

In short: Personalis agreed to be acquired by Tempus AI for $1.5 billion and received UKCA marking for its NeXT Personal Dx cancer test.

Company announcements

July 20 Personalis

Personalis announces its acquisition by Tempus for $1.5 billion

The all-stock deal integrates Personalis MRD technology into Tempus AI platform. Closing is expected in late 2026 or early 2027.

July 14 Personalis

Personalis obtains UKCA marking for British MRD diagnostics

This approval enables clinical deployment across England, Wales, and Scotland while bolstering multinational oncology trials through a commercial partnership with Link Medical Solutions Ltd.

June 10 Personalis

Personalis obtains CE-IVD marking for specimen collection kits

This regulatory milestone enables global deployment of Next Personal MRD testing in EU and UK clinical trials.

May 26 Personalis

Personalis highlights MRD test performance at ASCO 2026

The NeXT Personal assay demonstrates ultrasensitive minimal residual disease detection across colorectal, lung, ovarian, endometrial, melanoma, and kidney cancers, supporting earlier clinical intervention.

Media coverage

August 19 Nikkei Biotech Online

US Tempus acquires US Personalis, a partner with ultra-sensitive blood tumor DNA detection technology

US Tempus AI announced on July 20, 2026, that it will acquire its partner, US Personalis. Personalis develops liquid biopsy test products that contribute to cancer precision medicine, and its cancer minimal residual disease (MRD) test "NeXT Personal Dx" is co-marketed by Tempus. Tempus, which provides precision medicine support services through data services utilizing artificial intelligence (AI), is the same...

August 7 Finanzen.ch

Personalis: Balance sheet figures for the previous quarter

Personalis published the figures for the annual quarter ending on June 30, 2026, at the all-three-month financial conference on August 4, 2026. The...

July 21 The Globe and Mail

Personalis to Be Acquired by Tempus AI in Merger

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities...

July 20 The Globe and Mail

Tempus AI to Acquire Personalis in $1.5 Billion Deal to Expand Precision Oncology Platform

Tempus AI ($TEM) has agreed to acquire Personalis ($PSNL) in an all-stock transaction valued at approximately $1.5 billion in enterprise value, expanding its capabilities in...

Never miss news about Personalis

Track Personalis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Personalis competitors & trending companies

Browse news for competitors to Personalis and other trending companies.